Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2012 Dec 5;121(2):237–243. doi: 10.1289/ehp.1205731

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Publication of EHP lies in the public domain and is therefore without copyright. All text from EHP may be reprinted freely. Use of materials published in EHP should be acknowledged (for example, ?Reproduced with permission from Environmental Health Perspectives?); pertinent reference information should be provided for the article from which the material was reproduced. Articles from EHP, especially the News section, may contain photographs or illustrations copyrighted by other commercial organizations or individuals that may not be used without obtaining prior approval from the holder of the copyright.

PMC Copyright notice

Inhibitory effect of iAs³⁺ on the transcriptional activity of C/EBPβ and expression of PPARγ and C/EBPs during adipogenesis in 3T3-L1 preadipocytes. Abbreviations: C/EBPβ (LAP), C/EBPβ isoform liver-enriched activator protein; C/EBPβ (LIP), C/EBPβ isoform liver-enriched inhibitory protein; Control, cells were differentiated using the DMI protocol for the indicated time; iAs³⁺, cells were treated with iAs³⁺ (5 μM) during DMI treatment; vehicle, cells were maintained in growth medium without DMI. (A) mRNA expression of Cebps and Pparγ at the same differentiation time (n = 3). (B) Effects of DMI treatment on protein expression of PPARγ and C/EBPs during adipogenesis. Two isoforms of C/EBPα (42 kDa and 30 kDa) are shown on the blot. (C) Representative images of immunostaining of nuclear C/EBPβ after 16-hr DMI treatment. (D) Quantification of fluorescence intensity of nuclear C/EBPβ shown in (C) (n = 4–5). (E) Activity of C/EBP-luciferase reporter following DMI treatment in control and iAs³⁺-treated vs. control cells.